Home › Switching GLP-1 medicines
Switching between GLP-1 medicines in the UK
About this page. Written by the GLPInfo editorial team with AI assistance from the official sources listed at the end, and approved by the site owner before publication. It has not been reviewed by a named clinician. Published 27 Aug 2026 · last updated 27 Aug 2026 · next scheduled review 27 Nov 2026.
This page is information, not medical advice. It never tells you which medicine, dose or format is right for you: those decisions sit with you and a qualified prescriber. Spotted an error? Tell us and we'll fix it fast.
With four licensed options (two injections, two tablets), switching is now one of the most common questions in UK weight management: injection to tablet for convenience, or between brands for tolerability, availability or price. Here is what a switch actually involves, and what it costs.
The clinical part is prescriber-led, and that is not small print
There is no published universal conversion chart between tirzepatide, semaglutide and orforglipron doses. The medicines act on overlapping but different receptor profiles, and equivalent appetite effect does not map neatly across milligram numbers. A prescriber deciding your switch considers what dose you tolerated, why you are switching, and whether to start the new medicine at its own early step rather than jumping to a "matching" level. Expect a conservative restart more often than a straight swap, and expect the provider's clinical team to ask about your current treatment in their assessment.
The three common switch paths
Injection to tablet. The draw is routine: no needles, no fridge, and with Foundayo no food rules either. The trade is trial-average effect, particularly coming from Mounjaro, whose SURMOUNT-1 average sits well above the tablets' trial results. Foundayo vs Mounjaro sets out that trade with sources.
Between injections. Mounjaro and Wegovy differ in mechanism, trial results and price ladder; the head-to-head evidence is in our Mounjaro vs Wegovy comparison.
Between tablets. The newest path. The practical difference is the Wegovy pill's fasting rules against Foundayo's none; the full picture is in Foundayo vs the Wegovy pill.
The money part: what switching really costs
Switching medicine usually means re-entering a titration ladder, and switching provider usually means losing new-customer pricing you already used. Check the ongoing monthly price at the dose you would realistically stay on, not the first-month offer, and check both on the same day because prices move: every figure in our tables carries its checked date and re-checks every 12 hours. Start with the UK GLP-1 price index for the market at a glance, then the per-treatment comparisons: Mounjaro, Wegovy, Wegovy pill, Foundayo. If you are changing provider rather than medicine, run the checks in how to check a UK weight-loss provider first.
Frequently asked questions
Can I switch from Mounjaro or Wegovy to a tablet?
Only through a prescriber. Switching between GLP-1 medicines is a clinical decision: the medicines' leaflets do not publish universal dose-conversion tables, and the right starting dose on the new medicine depends on what you were taking, how you tolerated it, and your history. UK online providers run their own switching assessments; expect to be started conservatively rather than at an "equivalent" high dose.
Will I lose my discounted price if I switch providers?
Usually yes for intro pricing: most first-order offers are for new customers of that provider. Switching medicine with the SAME provider keeps your customer status but changes the medicine price. Our comparison tables separate first-order and ongoing prices exactly so you can see what a switch really costs.
Does weight come back when you switch?
Switching with continuous treatment is not stopping. What the trials measure is regain after full discontinuation. A properly managed switch aims for continuity; ask the prescriber how they manage any gap between medicines.